ARTICLE | Company News

Chimerix gives update on brincidofovir, CMX16669

October 16, 2014 3:27 AM UTC

Chimerix Inc. (NASDAQ:CMRX) announced next steps for development of brincidofovir to treat Ebola and other viral infections in an R&D update. The company also plans to file an IND for CMX16669 to treat cytomegalovirus (CMV).

President and CEO Michelle Berrey said the Phase II protocol for brincidofovir to treat Ebola patients in the U.S. and EU is under review. FDA accepted an emergency IND on Oct. 6, and the therapy was given to an Ebola patient who later died in a Dallas hospital (see BioCentury Extra, Oct. 6). ...